Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) announced the addition of their noninvasive cancer detection test, CyPath® Lung, to the Federal Supply Schedule (FSS) for the Veterans Health Administration (VHA). This inclusion allows CyPath® Lung to be accessible to the VA's 1,380 healthcare facilities, including over 170 medical centers and 1,000 outpatient sites. The VHA, serving 9.1 million veterans annually, is the largest integrated healthcare system in the U.S. The announcement was made during a joint presentation with FSS officials at the National Association of Veterans’ Research and Education Foundations (NAVREF) meeting. This collaboration aims to improve lung cancer detection and care for veterans, who are at higher risk due to factors like older age, smoking, and environmental exposure. CyPath® Lung aids in bridging the gap between initial screening results and invasive procedures, offering a significant opportunity for bioAffinity Technologies.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) ha annunciato l'inserimento del loro test di rilevazione del cancro non invasivo, CyPath® Lung, nel Federal Supply Schedule (FSS) per la Veterans Health Administration (VHA). Questa inclusione consente a CyPath® Lung di essere accessibile alle 1.380 strutture sanitarie della VA, comprese oltre 170 centri medici e 1.000 siti ambulatoriali. La VHA, che serve annualmente 9,1 milioni di veterani, è il più grande sistema sanitario integrato negli Stati Uniti. L'annuncio è stato fatto durante una presentazione congiunta con i funzionari del FSS al meeting della National Association of Veterans’ Research and Education Foundations (NAVREF). Questa collaborazione mira a migliorare la rilevazione e la cura del cancro ai polmoni per i veterani, che sono a maggior rischio a causa di fattori come l'età avanzata, il fumo e l'esposizione ambientale. CyPath® Lung aiuta a colmare il divario tra i risultati dello screening iniziale e le procedure invasive, offrendo un'opportunità significativa per bioAffinity Technologies.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) anunció la inclusión de su prueba de detección de cáncer no invasiva, CyPath® Lung, en el Federal Supply Schedule (FSS) para la Veterans Health Administration (VHA). Esta inclusión permite que CyPath® Lung sea accesible a las 1,380 instalaciones de salud de la VA, incluyendo más de 170 centros médicos y 1,000 sitios ambulatorios. La VHA, que atiende a 9.1 millones de veteranos anualmente, es el sistema de salud integrado más grande de EE. UU. El anuncio se realizó durante una presentación conjunta con funcionarios del FSS en la reunión de la National Association of Veterans’ Research and Education Foundations (NAVREF). Esta colaboración tiene como objetivo mejorar la detección y el cuidado del cáncer de pulmón en veteranos, quienes tienen un mayor riesgo debido a factores como la edad avanzada, el tabaquismo y la exposición ambiental. CyPath® Lung ayuda a cerrar la brecha entre los resultados de las pruebas iniciales y los procedimientos invasivos, ofreciendo una oportunidad significativa para bioAffinity Technologies.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW)는 Veterans Health Administration (VHA)용 연방 조달 일정(FSS)에 비침습적 암 검출 테스트인 CyPath® Lung의 추가를 발표했습니다. 이 포함으로 CyPath® Lung는 VA의 1,380개 의료 시설, 170개 이상의 의료 센터 및 1,000개 이상의 외래 진료소에서 접근할 수 있게 되었습니다. 매년 910만 명의 재향군인을 대상으로 하는 VHA는 미국에서 가장 큰 통합 의료 시스템입니다. 이 발표는 National Association of Veterans’ Research and Education Foundations(NAVREF) 회의에서 FSS 관계자와의 공동 발표 중에 이루어졌습니다. 이 협업은 나이, 흡연, 환경 노출과 같은 요인으로 인해 높은 위험에 처한 재향군인을 위한 폐암 검출 및 치료 개선을 목표로 합니다. CyPath® Lung는 초기 검사 결과와 침습적 절차 간의 간극을 메우는 데 도움을 주며, bioAffinity Technologies에 중요한 기회를 제공합니다.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) a annoncé l'ajout de son test de détection du cancer non invasif, CyPath® Lung, au Federal Supply Schedule (FSS) pour l'Administration des anciens combattants (VHA). Cette inclusion permet à CyPath® Lung d'être accessible aux 1 380 établissements de santé de la VA, y compris plus de 170 centres médicaux et 1 000 sites de soins ambulatoires. La VHA, qui dessert 9,1 millions d'anciens combattants chaque année, est le plus grand système de santé intégré aux États-Unis. L'annonce a été faite lors d'une présentation conjointe avec les responsables du FSS lors de la réunion de la National Association of Veterans’ Research and Education Foundations (NAVREF). Cette collaboration vise à améliorer la détection et les soins du cancer du poumon pour les anciens combattants, qui sont à risque accru en raison de facteurs tels que l'âge avancé, le tabagisme et l'exposition environnementale. CyPath® Lung aide à combler le fossé entre les résultats des dépistages initiaux et les procédures invasives, offrant une opportunité significative pour bioAffinity Technologies.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) hat die Aufnahme ihres nicht-invasiven Krebsdiagnosetests CyPath® Lung in den Federal Supply Schedule (FSS) für die Veterans Health Administration (VHA) bekannt gegeben. Diese Aufnahme ermöglicht den Zugang zu CyPath® Lung für die 1.380 Gesundheitseinrichtungen der VA, darunter über 170 medizinische Zentren und 1.000 ambulante Einrichtungen. Die VHA, die jährlich 9,1 Millionen Veteranen betreut, ist das größte integrierte Gesundheitssystem in den USA. Die Bekanntgabe wurde während einer gemeinsamen Präsentation mit FSS-Beamten bei der National Association of Veterans’ Research and Education Foundations (NAVREF) Sitzung gemacht. Diese Zusammenarbeit zielt darauf ab, die Erkennung und Versorgung von Lungenkrebs bei Veteranen zu verbessern, die aufgrund von Faktoren wie älteren Lebensjahren, Rauchen und Umwelteinflüssen ein höheres Risiko haben. CyPath® Lung hilft dabei, die Lücke zwischen den Erstuntersuchungsergebnissen und invasiven Verfahren zu schließen und bietet bioAffinity Technologies eine bedeutende Gelegenheit.
- CyPath® Lung added to Federal Supply Schedule for VHA's 1,380 healthcare facilities.
- VHA serves 9.1 million veterans annually, providing a large market for CyPath® Lung.
- Significant opportunity for bioAffinity Technologies to expand its market reach.
- None.
Insights
The addition of CyPath® Lung to the Federal Supply Schedule represents a significant market expansion opportunity for bioAffinity Technologies. With access to 1,380 VA healthcare facilities serving 9.1 million veterans annually, this creates a substantial addressable market. Veterans are particularly relevant as a target demographic due to their higher risk factors for lung cancer, including age, smoking history and environmental exposures during service.
The partnership with the VHA, America's largest integrated healthcare system, provides a streamlined procurement pathway and validates CyPath® Lung's clinical utility. This development could accelerate market penetration and revenue generation, especially given the VA's active lung cancer screening programs like LPOP. The diagnostic's positioning as an intermediate step between LDCT screening and invasive procedures addresses a important clinical need while potentially reducing healthcare costs.
CyPath® Lung's integration into the VA healthcare system is strategically significant from a clinical perspective. The test fills a critical diagnostic gap by providing a noninvasive option for patients with indeterminate pulmonary nodules discovered during LDCT screening. This addresses a major clinical challenge where physicians must balance the risks of invasive procedures against the need for early cancer detection.
The veteran population represents an ideal demographic for this technology, given their elevated lung cancer risk profile. The test's ability to help differentiate between cases requiring immediate intervention versus watchful waiting could lead to more optimal patient care pathways and potentially better outcomes. This development aligns with the VA's commitment to precision oncology and could significantly impact their lung cancer management protocols.
The VHA, part of the
“The ability to sell CyPath® Lung to VA healthcare facilities, which include more than 170 medical centers and more than 1,000 outpatient sites across the country, opens a significant opportunity,” bioAffinity President and CEO Maria Zannes said. “We appreciate that NAVREF recognized the importance of sharing information about CyPath® Lung with our VA colleagues and helping the Foundations’ industry partners – including large pharmaceutical companies, biotech firms and medical partners – learn more about the invaluable assistance we received from the VA’s National Acquisition Center professional staff.”
"NAVREF is proud to support innovative collaborations like the one between bioAffinity Technologies and the Veterans Health Administration,” NAVREF Chief Executive Officer Rashi Romanoff said. “The inclusion of CyPath® Lung in the Federal Supply Schedule emphasizes the power of public-private partnerships to bring cutting-edge diagnostic tools to the VA, with the goal of improving health outcomes for veterans. We commend bioAffinity and the VA for their dedication to advancing lung cancer detection and care."
NAVREF is a nonprofit membership organization dedicated to advancing the vital work of research and education conducted by VA-affiliated nonprofits throughout the VA system. NAVREF provides resources, expertise, and advocacy to support its members in their mission to improve the lives of veterans through innovative research and educational initiatives. NAVREF has collaborated with the VA to streamline clinical trial opportunities for veterans, deliver cutting-edge care, and enhance education for VA healthcare staff, veterans, and their families. By prioritizing health innovation, NAVREF ensures that veterans benefit from groundbreaking research and accessible clinical trials across the nation. bioAffinity Technologies is a member of NAVREF’s Industry Partner Consortium.
Veterans are at higher risk for lung cancer due to older age, smoking and environmental exposure during and after military service. Through programs like the Lung Precision Oncology Program (LPOP), the VA promotes annual lung cancer screening for high-risk individuals. CyPath® Lung is especially effective for patients who receive a positive screening result. When a low dose computed tomography (LDCT) scan reveals indeterminate pulmonary nodules, CyPath® Lung helps close the gap between a “wait and see” option and an invasive procedure, including biopsy, that may turn out to be unnecessary.
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the ability to sell CyPath® Lung to more than 170 medical centers and more than 1,000 outpatient sites across the country and access to VA medical facilities opening a significant opportunity. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to increase sales due to its access to VA medical facilities and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205274108/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
What is CyPath® Lung's significance for BIAF?
How many veterans are served by the VHA annually?
What is the impact of CyPath® Lung on lung cancer detection?
Where was the announcement about CyPath® Lung made?
